Sugi Predict

Sugi Predict / Compounds / SCHEMBL826649

SCHEMBL826649

SCHEMBL826649

CC(=O)C(=O)c1ccc(CC(N)C(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 5/20 0.62
▸ PTGS1 P23219 3/20 0.61
▸ ALPI P09923 1/20 0.61
▸ PKM P14618 1/20 0.61
▸ XIAP P98170 1/20 0.61
▸ TPH1 P17752 2/20 0.61
▸ HIF1A Q16665 4/20 0.53
▸ ALOX15 P16050 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ USP2 O75604 1/20 0.53
▸ EGFR P00533 1/20 0.53
▸ LCK P06239 1/20 0.53
▸ FYN P06241 1/20 0.53
▸ ADORA3 P0DMS8 1/20 0.53
▸ HTR2A P28223 1/20 0.53
▸ PTGS2 P35354 1/20 0.53
▸ RECQL P46063 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ GRB2 P62993 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12142607 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL6777440 0.85 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL93537 0.85 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL93538 0.85 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL12142616 0.85 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL13410540 0.85 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL3736020 0.85 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL12142605 0.85 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2310526 0.84 SLC7A5 (0.83) SLC7A5PTGS1ALPIPKMXIAP
Ammonia Solution, Strong SCHEMBL18166510 0.84 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037405-B2 Anti-CD70 antibody drug conjugates AMBRX, INC. 2024-07-16 — — US disclosed
US-12037405-B2 Anti-CD70 antibody drug conjugates AMBRX, INC. 2024-07-16 — — US disclosed
EP-4389145-A2 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND THEIR USES Ambrx, Inc. (US) 2024-06-26 — — EP disclosed
US-11786578-B2 Modified relaxin polypeptides and their uses AMBRX, INC. (US) 2023-10-17 — — US disclosed
US-11786578-B2 Modified relaxin polypeptides and their uses AMBRX, INC. (US) 2023-10-17 — — US disclosed
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2023-09-28 — — US disclosed
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2023-09-28 — — US disclosed
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates AMBRX, INC. (US) 2023-09-21 — — US disclosed
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates AMBRX, INC. (US) 2023-09-21 — — US disclosed
US-20230226152-A1 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF AMBRX, INC. 2023-07-20 — — US disclosed
US-20080102124-A1 Modified Human Growth Hormone AMBRX, INC. (US) 2008-05-01 — — US disclosed
US-20080102124-A1 Modified Human Growth Hormone AMBRX, INC. (US) 2008-05-01 — — US disclosed
US-20080102125-A1 Modified Human Growth Hormone AMBRX, INC. (US) 2008-05-01 — — US disclosed
US-20080102125-A1 Modified Human Growth Hormone AMBRX, INC. (US) 2008-05-01 — — US disclosed
WO-2008030558-A2 MODIFIED HUMAN PLASMA POLYPEPTIDE OR FC SCAFFOLDS AND THEIR USES AMBRX, INC. (US) 2008-03-13 — — WO disclosed
US-7332571-B2 Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses AMBRX, INC. (US) 2008-02-19 — — US disclosed
US-7332571-B2 Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses AMBRX, INC. (US) 2008-02-19 — — US disclosed
WO-2007094916-A2 NON-NATURAL AMINO ACID POLYPEPTIDES HAVING MODULATED IMMUNOGENICITY AMBRX, INC. (US) 2007-08-23 — — WO disclosed
WO-2006069220-A9 MODIFIED HUMAN GROWTH HORMONE AMBRX INC (US) 2007-08-02 — — WO disclosed
WO-2007079130-A2 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES AMBRX, INC. (US) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226152-A1 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF IL2, IL2RA, TAP2 SLC7A5 2199/4885PTGS1 2216/4885ALPI 3732/4885
US-12037405-B2 Anti-CD70 antibody drug conjugates CD74, CD63, CD47 SLC7A5 264/4885PTGS1 4544/4885ALPI 2388/4885
US-20080102124-A1 Modified Human Growth Hormone GHRHR, GHITM, GHSR SLC7A5 2983/4885PTGS1 3265/4885ALPI 1783/4885
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF TLR3, TLR1, TLR9 SLC7A5 2905/4885PTGS1 2511/4885ALPI 2703/4885
US-20080102125-A1 Modified Human Growth Hormone GHRHR, GHITM, GHSR SLC7A5 2983/4885PTGS1 3265/4885ALPI 1783/4885
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates CD63, CD74, CD99 SLC7A5 221/4885PTGS1 4492/4885ALPI 1996/4885
US-11786578-B2 Modified relaxin polypeptides and their uses RXFP1, RXFP2, RXFP3 SLC7A5 2122/4885PTGS1 644/4885ALPI 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.